CTLA4 and cancer: Alternative methods of reactivating the anti-cancer immune response are being actively investigated, the most successful of which involve neutralizing antibodies targeting immune checkpoint inhibitors such as PD-1 and CTLA-4 (Alsaab et al., 2017; Sharpe and Pauken, 2018; Tang et al., 2018).